Official Title
Low-Level Laser Therapy Treatment of Lung Inflammation in COVID-19 Patients
Brief Summary

To determine if a reduction of pneumonic inflammation occurs after treatment with Low-Level Laser Therapy (LLLT) applying red-light technology in the respiratory system of COVID-19 patients suffering from acute viral pneumonia.

Detailed Description

This clinical trial is a blinded before and after comparison of the effect on patients
treated with a red-light LLLT therapy for acute lung inflammation as a result of COVID-19
infection. Patients are enrolled to undergo LLLT therapy in addition to all standard ongoing
therapies for COVID-19.

Outcomes for patients receiving LLLT in addition to their standard care (the treatment group)
are compared to the group receiving only standard therapy for COVID-19 (control group).
Effects of LLLT treatment are measured immediately following treatment, and outcome
measurements are compared to the pre-treatment baseline.

Withdrawn
COVID19

Device: Non-invasive red LLLT treatment to chest of patient.

Expose patient to LLLT light while lying on their back, elevated at an angle of approximately 45 degrees from horizontal. Position light over the patient's chest at a 33-degree bias to their right and left sides for 20 minutes each side respectively.

Device: Sham Device Treatment

Expose patient to sham device while lying on their back, elevated at an angle of approximately 45 degrees from horizontal. Position light over the patient's chest at a 33-degree bias to their right and left sides for 20 minutes each side respectively.

Eligibility Criteria

Inclusion Criteria:

- Participant is diagnosed with COVID-19.

- Study participant is 18 years of age or older.

- Patient exhibiting moderate-to-acute respiratory distress.

Exclusion Criteria:

- Photosensitive condition or medication.

- Active chemotherapy treatment or other cancer treatment.

- Autoimmune Disorder.

- Pregnant, possibly pregnant or planning pregnancy prior to the end of study
participation.

- Developmental disability or cognitive impairment that, in the opinion of the
investigator, would preclude adequate comprehension of the informed consent form
and/or ability to record the necessary study measurements.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
United States
Locations

Wellness Junction
Millsboro, Delaware, United States

Rober H Burke, MD, Principal Investigator
Michigan Center for Cosmetic Surgery

Ward Photonics LLC
NCT Number
MeSH Terms
COVID-19
Pneumonia
Inflammation